Agency for Healthcare Research and Quality; Notice of Meeting, 31450 [2010-13108]
Download as PDF
<![CDATA[
31450
Federal Register / Vol. 75, No. 106 / Thursday, June 3, 2010 / Notices
and discussed at this meeting. These
discussions are likely to reveal personal
information concerning individuals
associated with the applications. This
information is exempt from mandatory
disclosure under the above-cited
statutes.
SEP Meeting on: AHRQ Limited
Competition: PROSPECT STUDIES—
Building New Clinical Infrastructure for
CE (R01).
Date: June 16, 2010 (Open on June 16
from 8 a.m. to 8:15 a.m. and closed for
the remainder of the meeting).
Place: Hyatt Regency Bethesda Hotel,
7400 Wisconsin Avenue, 1 Bethesda
Metro Center, Bethesda, Maryland
20814.
Contact Person: Anyone wishing to
obtain a roster of members, agenda or
minutes of the non-confidential portions
of this meeting should contact Mrs.
Bonnie Campbell, Committee
Management Officer, Office of
Extramural Research, Education and
Priority Populations, AHRQ, 540
Gaither Road, Room 2038, Rockville,
Maryland 20850, Telephone (301) 427–
1554.
Agenda items for this meeting are
subject to change as priorities dictate.
Dated: May 24, 2010.
Carol M. Clancy,
Director.
[FR Doc. 2010–13109 Filed 6–2–10; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality; Notice of Meeting
sroberts on DSKD5P82C1PROD with NOTICES
In accordance with section 10(d) of
the Federal Advisory Committee Act (5
U.S.C., Appendix 2), announcement is
made of a Health Care Policy and
Research Special Emphasis Panel (SEP)
meeting.
A Special Emphasis Panel is a group
of experts in fields related to health care
research who are invited by the Agency
for Healthcare Research and Quality
(AHRQ), and agree to be available, to
VerDate Mar<15>2010
18:21 Jun 02, 2010
Jkt 220001
conduct on an as-needed basis,
scientific reviews of applications for
AHRQ support. Individual members of
the Panel do not attend regularlyscheduled meetings and do not serve for
fixed terms or a long period of time.
Rather, they are asked to participate in
particular review meetings which
require their type of expertise.
Substantial segments of the upcoming
SEP meeting listed below will be closed
to the public in accordance with the
Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications for the OS ARRA:
Optimizing Prevention and Healthcare
Management for Complex Patients (R21)
applications are to be reviewed and
discussed at this meeting. These
discussions are likely to reveal personal
information concerning individuals
associated with the applications. This
information is exempt from mandatory
disclosure under the above-cited
statutes.
SEP Meeting on: OS ARRA:
Optimizing Prevention and Healthcare
Management for Complex Patients
(R21).
Date: June 24, 2010 (Open on June 24
from 8 a.m. to 8:15 a.m. and closed for
the remainder of the meeting).
Place: Hilton Rockville Executive
Meeting Center, 1750 Rockville Pike,
Conference Room TBD, Rockville, MD
20850.
Contact Person: Anyone wishing to
obtain a roster of members, agenda or
minutes of the nonconfidential portions
of this meeting should contact Mrs.
Bonnie Campbell, Committee
Management Officer, Office of
Extramural Research, Education and
Priority Populations, AHRQ, 540
Gaither Road, Room 2038, Rockville,
Maryland 20850, Telephone (301) 427–
1554.
Agenda items for this meeting are
subject to change as priorities dictate.
Dated: May 24, 2010.
Carolyn M. Clancy,
Director.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0004]
[FDA 225–09–0014]
Memorandum of Understanding by and
Between the United States Food and
Drug Administration and the
International Anesthesia Research
Society for the Safety of Key Inhaled
and Intravenous Drugs in Pediatrics
Public-Private Partnership
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is providing
notice of a memorandum of
understanding (MOU) between FDA and
the International Anesthesia Research
Society (IARS). The purpose of this
MOU is to establish a framework for
collaboration between FDA and IARS
and to support their shared interest of
promoting the safe use of anesthetics
and sedatives in children.
DATES: The agreement became effective
March 21, 2010.
FOR FURTHER INFORMATION CONTACT:
Wendy R. Sanhai, Senior Scientific
Advisor, Office of the Commissioner,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 32, rm.
4128, Silver Spring, MD 20993, 301–
796–8518.
In
accordance with 21 CFR 20.108(c),
which states that all written agreements
and MOUs between FDA and others
shall be published in the Federal
Register, the agency is publishing notice
of this MOU.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2010–13108 Filed 6–2–10; 8:45 am]
Dated: May 26, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
BILLING CODE 4160–90–M
BILLING CODE 4160–01–S
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 75, Number 106 (Thursday, June 3, 2010)]
[Notices]
[Page 31450]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-13108]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality; Notice of Meeting
In accordance with section 10(d) of the Federal Advisory Committee
Act (5 U.S.C., Appendix 2), announcement is made of a Health Care
Policy and Research Special Emphasis Panel (SEP) meeting.
A Special Emphasis Panel is a group of experts in fields related to
health care research who are invited by the Agency for Healthcare
Research and Quality (AHRQ), and agree to be available, to conduct on
an as-needed basis, scientific reviews of applications for AHRQ
support. Individual members of the Panel do not attend regularly-
scheduled meetings and do not serve for fixed terms or a long period of
time. Rather, they are asked to participate in particular review
meetings which require their type of expertise.
Substantial segments of the upcoming SEP meeting listed below will
be closed to the public in accordance with the Federal Advisory
Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C.
552b(c)(6). Grant applications for the OS ARRA: Optimizing Prevention
and Healthcare Management for Complex Patients (R21) applications are
to be reviewed and discussed at this meeting. These discussions are
likely to reveal personal information concerning individuals associated
with the applications. This information is exempt from mandatory
disclosure under the above-cited statutes.
SEP Meeting on: OS ARRA: Optimizing Prevention and Healthcare
Management for Complex Patients (R21).
Date: June 24, 2010 (Open on June 24 from 8 a.m. to 8:15 a.m. and
closed for the remainder of the meeting).
Place: Hilton Rockville Executive Meeting Center, 1750 Rockville
Pike, Conference Room TBD, Rockville, MD 20850.
Contact Person: Anyone wishing to obtain a roster of members,
agenda or minutes of the nonconfidential portions of this meeting
should contact Mrs. Bonnie Campbell, Committee Management Officer,
Office of Extramural Research, Education and Priority Populations,
AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850, Telephone
(301) 427-1554.
Agenda items for this meeting are subject to change as priorities
dictate.
Dated: May 24, 2010.
Carolyn M. Clancy,
Director.
[FR Doc. 2010-13108 Filed 6-2-10; 8:45 am]
BILLING CODE 4160-90-M
